Halozyme Therapeutics (HALO) Finished Goods (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Finished Goods of $113.4 million for Q1 2026, down 20.85% year-over-year from $143.2 million in Q1 2025, and down 21.52% quarter-over-quarter from $144.5 million in Q4 2025.
Halozyme Therapeutics (HALO) Finished Goods (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Finished Goods for 16 consecutive years, with $113.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Finished Goods fell 20.85% year-over-year to $113.4 million; the TTM figure through Mar 2026 stood at $113.4 million (down 20.85% YoY), while the FY2025 annual figure was $144.5 million, up 1.06% from the prior year.
- Finished Goods fell to $113.4 million in Q1 2026 per HALO's latest filing, from $144.5 million in the prior quarter.
- Across five years, Finished Goods topped out at $164.9 million in Q2 2025 and bottomed at $31.2 million in Q1 2022.
- Historically, Finished Goods has averaged $96.6 million across 5 years, with a median of $95.8 million in 2024.
- Annual changes were most pronounced in 2024 — Finished Goods soared 122.79% — and 2026, when it declined 20.85%.
- Halozyme Therapeutics' Finished Goods stood at $46.0 million in 2022, then soared by 52.12% to $69.9 million in 2023, then soared by 104.41% to $142.9 million in 2024, then climbed by 1.06% to $144.5 million in 2025, then declined by 21.52% to $113.4 million in 2026.
- Business Quant data shows HALO's Finished Goods at $113.4 million in Q1 2026, $144.5 million in Q4 2025, and $161.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.18 Mn |
| Mar 31, 2026 | 113.37 Mn |
| Dec 31, 2025 | 144.45 Mn |
| Sep 30, 2025 | 161.59 Mn |
| Jun 30, 2025 | 164.87 Mn |
| Mar 31, 2025 | 143.24 Mn |
| Dec 31, 2024 | 142.94 Mn |
| Sep 30, 2024 | 143.52 Mn |
| Jun 30, 2024 | 126.64 Mn |
| Mar 31, 2024 | 95.82 Mn |
| Dec 31, 2023 | 69.93 Mn |
| Sep 30, 2023 | 64.42 Mn |
| Jun 30, 2023 | 57.86 Mn |
| Mar 31, 2023 | 57.67 Mn |
| Dec 31, 2022 | 45.97 Mn |
| Sep 30, 2022 | 35.07 Mn |
| Jun 30, 2022 | 43.26 Mn |
| Mar 31, 2022 | 31.16 Mn |
| Dec 31, 2021 | 25.79 Mn |
| Sep 30, 2021 | 26.15 Mn |